Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
ARDS is a severe disease in ICU, and could induce high mortality. Glycocalyx is an important matrix construction which covers endothelial cells, it could protect endothelial cells injury and the glycocalyx biomarkers could predict pulmonary injury.
Decorin is a member of the small leucine-rich proteoglycan (SLRP) family, contains a single glycosaminoglycan (GAG) chain and a core protein with 12 leucine-rich repeats. In the previous study, decorin is associated with cardiac and liver fibrosis, however, the effects of decorin on ARDS pulmonary fibrosis have not been clarified.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Mild ARDS | patients have mild ARDS according to Berlin definition |
| |
| Moderate ARDS | patients have moderate ARDS according to Berlin definition |
| |
| Severe ARDS | patients have severe ARDS according to Berlin definition |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Glycocalyx measurement,respiratory mechanics measurement | Diagnostic Test | ELASA measure glycocalyx, measure plateau pressure, driving pressure |
|
| Measure | Description | Time Frame |
|---|---|---|
| 28 days mortality from patients involved in the study | 28 days mortality from patients involved in the study | 28 days |
| Measure | Description | Time Frame |
|---|---|---|
| CT and syndecan-1 to evaluate pulmonary fibrosis | pulmonary fibrosis evaluated by biomarker and CT | 1mon, 3mon and 6 month |
| pulmonary function test to evaluate pulmonary function | pulmonary function evaluated by pulmonary function test |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
patients have been diagnosed ARDS with mechanical ventilation, and do not been used heparin, molecular heparin, chondroitin sulfuric acid.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Chun C Pan, Dr | Contact | +862583262550 | panchun1982@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Chun C Pan, Dr | Zhongda hospital, Southeast University, Jiangsu, China | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Zhongda Hospital, Southeast University | Nanjing | Jiangsu | 210009 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012128 | Respiratory Distress Syndrome |
| D011658 | Pulmonary Fibrosis |
| ID | Term |
|---|---|
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D012120 | Respiration Disorders |
| D017563 | Lung Diseases, Interstitial |
Not provided
Not provided
Not provided
Not provided
Not provided
blood and urine
| 1mon, 3mon and 6 month |
| D005355 | Fibrosis |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |